Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal
By Ludwig Burger and Dina Kartit (Reuters) -France’s Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug pipeline following development setbacks. The deal would give the French drugmaker full ownership of the approved Tzield injection to delay progression of type …
Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal Read More »








